November 15, 2022
Breathdx.ai (previously known as Blu Biotech) has formed a collaboration with University of Michigan (U-M) and its Max Harry Weil Institute for Critical Care Research and Innovation to develop the breath biomarkers for the detection of Sepsis and acute respiratory distress syndrome (ARDS). Once clinical research has concluded, Breathdx.ai (previously known as Blu Biotech) will seek FDA approval for the use of the discovered biomarkers in their proprietary Micro GC device which was recently licensed by U-M to Breathdx.ai (previously known as Blu Biotech).
November 2, 2022
Breathdx.ai (previously known as Blu Biotech) entered into a Patent License Agreement with Innovation Partnerships at the University of Michigan (U-M) to develop and commercialize a Micro Gas Chromatography Photoionization Detector (Micro-GC-PID), that uses a patient’s breath to diagnose various forms of cancer, COVID-19 and related variants, acute respiratory distress syndrome (ARDS), sepsis, and other acute and chronic inflammatory diseases. This novel diagnostic testing device was developed at the College of Engineering and the Weil Institute for Critical Care Research and Innovation through the efforts of Dr. Xudong Fan of the Department of Biomedical Engineering and Dr. Kevin Ward of the Department of Emergency Medicine at U-M.
